Coegin Pharma (NGM:COEGIN) Total Debt per Share: kr0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:COEGIN Coegin Pharma NGM:COEGIN
17 GF Score
Price kr2.96
! 3 Warning Signs
View Full Analysis

What is Coegin Pharma Total Debt per Share?

Coegin Pharma NGM:COEGIN +5.71% 17 Total Debt per Share is kr0.00 as of Jun. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 17/100. The stock has 3 warning signs investors should review.

kr0.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Coegin Pharma's Total Debt Per Share for the quarter that ended in Jun. 2026 was kr0.00.

Coegin Pharma Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Coegin Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma Total Debt per Share Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Coegin Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGM:COEGIN
17GF Score
Coegin Pharma NGM:COEGIN
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coegin Pharma Total Debt per Share Calculation

Coegin Pharma's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/24.88
=0.00

Coegin Pharma's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/28.59
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of kr0.00 mean?
Coegin Pharma (NGM:COEGIN) has a Total Debt per Share of kr0.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Coegin Pharma and its competitors.
Is Coegin Pharma's Total Debt per Share too high?
Coegin Pharma's current Total Debt per Share is kr0.00. Overall, Coegin Pharma has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Total Debt per Share compare to VRTX and REGN?
Coegin Pharma's Total Debt per Share of kr0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Coegin Pharma and its competitors. Coegin Pharma's current Total Debt per Share is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Total Debt per Share of kr0.00. The current Total Debt per Share is kr0.00. Coegin Pharma's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Total Debt per Share is kr0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coegin Pharma Business Description

Other Exchanges 7Z6:Germany
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
17GF Score

Get the complete analysis for NGM:COEGIN

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.96
Price